Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is a India-based company that develops and manufactures non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company provides contract development and manufacturing (CDMO) services to multinational and specialty pharmaceutical companies. Their primary areas of focus include cardiovascular disease, central nervous system disorders, diabetes, oncology, pain management, and anti-infectives.
In addition to these areas, Alivus also develops APIs for antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary, and anti-spasmodic treatments. The company has a diverse portfolio of around 151 molecules and supplies its products to customers in various regions around the world, including India, Europe, North America, Latin America, Japan, and the rest of the world.
Alivus has four manufacturing facilities located in Ankleshwar, Dahej, Mohol, and Kurkumbh, which enables the company to meet the diverse needs of its customers. With a strong presence in the pharmaceutical industry, Alivus is well-positioned to continue growth and expansion in the future.